glimepiride

Glimepiride (HOE-490) is a long-acting, third-generation sulfonylurea with hypoglycemic activity.

Glimepiride urethane is a third generation sulfonylurea compound, which increases the release of insulin from pancreatic beta cells. In addition, glimepiride increases the activity of intracellular insulin receptors. Glimepiride increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway. Furthermore, Glimepiride enhances intrinsic peroxisome proliferator-activated receptor γ activity. Glimepiride also increases protein expression of glucose transports 1 and 4, and is a potent KIR channel blocker.

trans-carboxy Glimepiride is a metabolite of the sulfonylurea glimepiride .1It is formed from glimepiride in a two-step process mediated by the cytochrome P450 (CYP) isoform CYP2C9 and cytosolic enzymes. 1.Noh, K., Kim, E., Jeong, T.C., et al.Simultaneous determination of glimepiride and its metabolites in human plasma by liquid chromatography coupled to a tandem mass spectrometryArch. Pharm. Res.34(12)2073-2078(2011)

trans-Hydroxy Glimepiride is an active metabolite of the sulfonylurea glimepiride, formed primarily in the liver by the cytochrome P450 (CYP) isoform CYP2C9.

Glimepiride sulfonamide is an antiinflammatory agent.

Glimepiride-d8 (Glimperide-d8; HOE-490-d8) is the deuterium-labeled form of Glimepiride.

Glimepiride-d4-1 is the deuterated form of Glimepiride. Glimepiride (Glimperide) is an antidiabetic compound belonging to the medium- to long-acting sulfonylurea class, with an ED50 of 182 μg/kg.

Glimepiride-d5 is the deuterated form of Glimepiride. Glimepiride (Glimperide) is a medium-to-long-acting sulfonylurea antidiabetic compound, with an ED50 of 182 μg/kg.

Glimepiride (Standard) is the standard substance of Glimepiride, suitable for quantitative analysis, quality control, and biochemical experiments, etc. Glimepiride (HOE-490) is a sulfonylurea anti-diabetic compound.